Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:46:29.597Z.
Calculation as of: 2026-10-06T13:46:29.597Z.
Quote observation: 2026-10-06T13:45:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5d6bd3278d76725a85d4cb05495e45b99d0fd89b23371e3701c8289362793e8f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$768.46M
PS Ratio
18.53
TTM Avg
12.05
3Y Avg
176.43
5Y Avg
968.45
Market Cap
$751.69M
PS Ratio
12740.48
TTM Avg
4690.70
3Y Avg
1617.75
5Y Avg
973.20
Market Cap
$761.28M
PS Ratio
N/A
TTM Avg
1076.18
3Y Avg
1003.10
5Y Avg
1003.10
Market Cap
$726.81M
PS Ratio
324.18
TTM Avg
191.08
3Y Avg
130.74
5Y Avg
130.74
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $766.35M | N/A | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $768.46M | 18.53 | 12.05 | 176.43 | 968.45 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $751.69M | 12740.48 | 4690.70 | 1617.75 | 973.20 |
| Geron Corporation (GERN)vs › | $776.24M | 3.79 | 4.98 | 1623.75 | 1489.80 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $790.35M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $761.28M | N/A | 1076.18 | 1003.10 | 1003.10 |
| AdaptHealth Corp. (AHCO)vs › | $786.39M | 0.26 | 0.48 | 0.44 | 0.69 |
| Cytek Biosciences, Inc. (CTKB)vs › | $794.39M | 3.84 | 2.95 | 3.49 | 6.67 |
| Anteris Technologies Global Corp. (AVR)vs › | $726.81M | 324.18 | 191.08 | 130.74 | 130.74 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $808.29M | 6.77 | 6.23 | 9.08 | 36.05 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-09 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-28 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-03 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
